相关实验视频
Updated: Jul 25, 2025
06:22
Modeling and Evaluation of Murine Diabetic Cardiomyopathy Model
Published on: November 29, 2024
671
在心力衰竭中使用-葡萄糖共运输体2抑制剂 - - 特殊人群中的当前证据
Gassan Moady1,2, Tuvia Ben Gal3,4, Shaul Atar1,2
1Department of Cardiology, Galilee Medical Center, Nahariya 2210001, Israel.
Life (Basel, Switzerland)
|June 28, 2023
概括
-葡萄糖共载体2 (SGLT2) 抑制剂提供了除糖尿病治疗之外的心血管和功能益处. 本综述探讨了它们在心力衰竭和病患者中的扩大应用,强调了安全性和有效性.
科学领域:
- 心脏病学 心脏病学
- 腎臟病學 (nephrology) 是一種醫學.
- 内分泌学 在内分泌学.
背景情况:
- 起初用于糖尿病的-葡萄糖共载体2 (SGLT2) 抑制剂显示出显著的心血管和益.
- 这些药物减少了心力衰竭住院,并改善了2型糖尿病患者的治疗结果.
- 新出现的证据支持SGLT2抑制剂在心力衰竭中具有减少和保存的射出分数 (HFrEF/HFpEF) 和慢性病 (CKD).
研究的目的:
- 对特殊患者群体中SGLT2抑制剂的当前数据进行审查.
- 讨论除了糖尿病之外的SGLT2抑制剂对心血管和的影响.
- 探索SGLT2抑制剂对心血管的益处的潜在机制.
主要方法:
- 临床试验和观察性研究的文献综述.
- 对心力衰竭,慢性病和其他特殊人群中SGLT2抑制剂的数据分析.
- 讨论拟议的行动机制.
主要成果:
- SGLT2 抑制剂在减少心力衰竭住院和改善心血管结果方面表现出有效性.
- 在患有HFpEF和CKD的患者中观察到有益效果,独立于糖尿病状况.
- 这些药物表现出良好的安全性,具有较低的生殖尿路感染和酸性的风险.
结论:
- 在不同患者群体中,SGLT2抑制剂是心血管和脏保护的有价值的治疗剂.
- 进一步的研究是有必要的,以阐明机制和扩大指示.
- SGLT2 抑制剂在治疗心力衰竭和慢性病方面取得了重大进展.
相关概念视频
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
240
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
240
01:30Heart Failure V: Medical Management
15
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
15
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
467
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
467
01:26Heart Failure Drugs: Inotropic Agents
640
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
640
01:55Secondary Active Transport
121.6K
One example of how cells use the energy contained in electrochemical gradients is demonstrated by glucose transport into cells. The ion vital to this process is sodium (Na+), which is typically present in higher concentrations extracellularly than in the cytosol. Such a concentration difference is due, in part, to the action of an enzyme “pump” embedded in the cellular membrane that actively expels Na+ from a cell. Importantly, as this pump contributes to the high concentration of...
121.6K
01:27Glucose Transporters
23.3K
Glucose transporters facilitate the transport of glucose across the cell membrane. In addition to glucose, some glucose transporters can also aid the movement of other hexoses such as fructose, mannose, and galactose.
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
23.3K